Low-dose cytotoxics as "anti-angiogenesis treatment" following adjuvant induction chemotherapy for patients with ER-negative and PgR-negative breast cancer

  • Biological Material / Translational Research

  • Serum Substudy

    Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in serum samples.

  • Results & Publications

Study Chair
Dr. Marco Colleoni - Milano, Italy

Dr. P. Kathryn Gray

Lead Trial Coordinator
Holly Shaw

Data Managers
Susan Fischer

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
November 22, 2000

Closure date
December 31, 2012

Targeted Accrual
1086 patients

Final Accrual
1086 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login